Advertisement
Advertisement
U.S. markets open in 1 hour 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Biocartis Group NV (8XB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.6690+0.0040 (+0.60%)
As of 08:05AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.6650
Open0.6690
Bid0.7000 x 105200
Ask0.7270 x 103100
Day's Range0.6690 - 0.6690
52 Week Range0.4640 - 2.8700
Volume480
Avg. Volume420
Market Cap67.105M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-1.2420
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8XB.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

      PRESS RELEASE - REGULATED INFORMATION 31 January 2023, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 31 January 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of January 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") conclud

    • GlobeNewswire

      Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES

      PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the Company has achieved its 2022 key business objectives focused on three performance indicators: Idylla™ product revenues, gross margins on product sales and operating cash burn. Based on non-audited numbers for 2022, Biocar

    • GlobeNewswire

      Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions

      PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today. The initial holders of the Company's 4.50% new second lien secured convertible

    Advertisement
    Advertisement